Here’s the translation to American English:
—
Champions Oncology has officially launched its new radiopharmaceutical services platform, marking a significant advancement in the field of translational oncology research. This launch follows the recent expansion of its radioactive materials license and the successful implementation of its radiochemical infrastructure, backed by the analysis of over thirty patient-derived xenograft models, in collaboration with pharmaceutical and biotechnology companies.
The company now offers fully integrated workflows in the area of radiopharmaceuticals, combining in vitro studies, biodistribution analysis in ex vivo models, and therapeutic efficacy. This innovative platform is distinguished by its extensive bank of PDX tumor models, allowing drug developers to evaluate radiolabeled agents in clinically relevant contexts, thereby facilitating the research and development of new treatments.
Mike Ritchie, the company’s Chief Commercial Officer, emphasized that “radiopharmaceuticals represent one of the most exciting frontiers in precision oncology.” He highlighted that the combination of their advanced radiochemical infrastructure with the renowned PDX bank provides clients with the opportunity to generate meaningful data that supports informed decisions in the early stages of oncology treatment development.
Champions’ new radioactive materials license includes support for ten key isotopes, such as Lu-177 and Ac-225, enabling a variety of studies ranging from radioligand therapy to theranostic approaches. Ritchie also stressed the goal of helping biopharmaceutical partners answer critical questions more swiftly, using data that reflects real tumor biology.
With this platform, Champions Oncology continues to position itself as a leading provider of preclinical and clinical research services in oncology, offering comprehensive R&D solutions to biopharmaceutical organizations worldwide. With its extensive service portfolio and focus on data quality, the company establishes itself as a key partner in advancing the discovery and development of oncology drugs.
Source: MiMub in Spanish
